4-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one | 866211-50-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one
• 英文别名: 4-Fluoro-3,3-dimethylindolin-2-one；4-fluoro-3,3-dimethyl-1H-indol-2-one
• CAS: 866211-50-9
• 化学式: C₁₀H₁₀FNO
• 分子量: 179.194
• InChiKey: TZNVQQZZBGDKSK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one 在 硫酸 、 硝酸 作用下， 反应 1.0h， 以2.2 g的产率得到4-fluoro-3,3-dimethyl-5-nitro-1,3-dihydro-2H-indol-2-one
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND

  摘要：

  本发明提供了一种由以下式（1）表示的化合物： 其中每个符号如规范中定义，或其盐，该化合物的前药或其盐，含有该化合物或其盐的药物，该药物是磷酸二酯酶10A抑制剂，以及用于预防或治疗精神分裂症的药物。

  公开号：

  US20130150344A1
• 作为产物：
  描述：

  methyl 2-(2-fluoro-6-nitrophenyl)-2-methylpropanoate 在 锌 作用下， 以 溶剂黄146 为溶剂， 反应 48.0h， 以93%的产率得到4-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one
  参考文献：
  名称：

  Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor

  摘要：

  Highly potent and brain-penetrant phosphodiesterase 10A (PDE10A) inhibitors based on the 2-oxindole scaffold were designed and synthesized. (2-Oxo-1,3-oxazolidin-3-yl) phenyl derivative 1 showed the high P-glycoprotein (P-gp) efflux (efflux ratio (ER) = 6.2) despite the potent PDE10A inhibitory activity (IC50 = 0.94 nM). We performed an optimization study to improve both the P-gp efflux ratio and PDE10A inhibitory activity by utilizing structure-based drug design (SBDD) techniques based on the X-ray crystal structure with PDE10A. Finally, 1-(cyclopropylmethyl)-4-fluoro-5-[5-methoxy-4-oxo-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-1(4H)-yl]-3,3-dimethyl-1,3-dihydro-2H-indol-2-one (19e) was identified with improved P-gp efflux (ER = 1.4) and an excellent PDE10A inhibitory activity (IC50 = 0.080 nM). Compound 19e also exhibited satisfactory brain penetration, and suppressed PCP-induced hyperlocomotion with a minimum effective dose of 0.3 mg/kg by oral administration in mice. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.10.002

文献信息

• Phenylaminopropanol derivatives and methods of their use
  申请人：Kim Younghee Callain

  公开号：US20050222148A1

  公开（公告）日：2005-10-06

  The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

  本发明涉及式I的苯胺丙醇衍生物： 或其药学上可接受的盐，含有这些衍生物的组合物，以及它们用于通过单胺再摄取改善的症状的预防和治疗方法，包括但不限于血管运动症状（VMS）、性功能障碍、胃肠道和泌尿系统疾病、慢性疲劳综合征、纤维肌痛综合征、神经系统疾病，以及其中的组合，特别是从包括重性抑郁障碍、血管运动症状、压力性和切勿性尿失禁、纤维肌痛、疼痛、糖尿病性神经病变以及其中的组合的一组中选择的那些症状。
• HETEROCYCLIC COMPOUND
  申请人：Yoshikawa Masato

  公开号：US20130150344A1

  公开（公告）日：2013-06-13

  The present invention provides a compound represented by the formula (1): wherein each symbol is as defined in the specification, or a salt thereof, a prodrug of the compound or a salt thereof, a medicament containing the compound or a salt thereof, the medicament which is a phosphodiesterase 10A inhibitor, and a medicament which is for preventing or treating schizophrenia.

  本发明提供了一种由以下式（1）表示的化合物： 其中每个符号如规范中定义，或其盐，该化合物的前药或其盐，含有该化合物或其盐的药物，该药物是磷酸二酯酶10A抑制剂，以及用于预防或治疗精神分裂症的药物。
• Design, Synthesis, and SAR of New Pyrrole-Oxindole Progesterone Receptor Modulators Leading to 5-(7-Fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1<i>H</i>-indol-5-yl)-1-methyl-1<i>H</i>-pyrrole-2-carbonitrile (WAY-255348)
  作者：Andrew Fensome、William R. Adams、Andrea L. Adams、Tom J. Berrodin、Jeff Cohen、Christine Huselton、Arthur Illenberger、Jeffrey C. Kern、Valerie A. Hudak、Michael A. Marella、Edward G. Melenski、Casey C. McComas、Cheryl A. Mugford、Ov D. Slayden、Matthew Yudt、Zhiming Zhang、Puwen Zhang、Yuan Zhu、Richard C. Winneker、Jay E. Wrobel

  DOI：10.1021/jm701080t

  日期：2008.3.1

  We have continued to explore the 3,3-dialkyl-5-aryloxindole series of progesterone receptor (PR) modulators looking for new agents to be used in female healthcare: contraception, fibroids, endometriosis, and certain breast cancers. Previously we reported that subtle structural changes with this and related templates produced functional switches between agonist and antagonist properties ( Fensome et

  我们继续探索3,3-二烷基-5-芳基吲哚系列孕酮受体（PR）调节剂，以寻找用于女性保健的新药物：避孕，肌瘤，子宫内膜异位症和某些乳腺癌。先前，我们报道了该模板和相关模板的微妙结构变化在激动剂和拮抗剂特性之间产生了功能转换（Fensome等，Biorg。Med。Chem。Lett。2002，12，3487; 2003，13，1317）。我们在本文中报道了5-（2-氧代吲哚-5-基）-1 H-吡咯-2-腈类化合物中的新功能开关。我们发现3，3-二烷基取代基的大小对于控制功能响应很重要。因此，小的基团（二甲基）提供有效的PR拮抗剂，而较大的基团（螺环己基）是PR激动剂。
• Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles
  申请人：Wilk Kazimierz Bogdan

  公开号：US20060247441A1

  公开（公告）日：2006-11-02

  Methods for preparing oxindole and thio-oxindole compounds are provided, which compounds are useful as precursors to useful pharmaceutical compounds. Specifically provided are methods for preparing 5-pyrrole-3,3-oxindole compounds and 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile. Also provided are methods for preparing iminobenzo[b]thiophene and benzo[b]thiophenone compounds.

  提供了制备氧吲哚和硫氧吲哚化合物的方法，这些化合物作为有用的药物化合物的前体。具体提供了制备5-吡咯-3,3-氧吲哚化合物和5-(7-氟-3,3-二甲基-2-氧代-2,3-二氢-1H-吲哚-5-基)-1-甲基-1H-吡咯-2-碳腈的方法。还提供了制备亚苄基苯并[b]噻吩和苯并[b]噻吩酮化合物的方法。
• Progesterone receptor antagonists, contraceptive regimens, and kits
  申请人：Grubb Sondermann Gary

  公开号：US20060009509A1

  公开（公告）日：2006-01-12

  A method of contraception is provided which involves delivery of 21 to 27 consecutive days of one or more PR antagonists in the absence of a progestin, estrogen, or other steroidal compound, followed by 1 to 7 days without any active agent. Also described is a pharmaceutically useful kit to facilitate delivery of this regimen.

  提供了一种避孕方法，涉及在没有孕激素、雌激素或其他类固醇化合物的情况下，连续给予21至27天的一种或多种PR拮抗剂，然后在没有任何活性药物的情况下进行1至7天。还描述了一个在药学上有用的工具包，以便实施这种方案的交付。